Conference Reports for NATAP

Conference on Retroviruses and Opportunistic Infections (CROI) February 13-16, 2017, Seattle WA Back

CROI 2017 HCV/HBV Reports       CROI: Summary from CROI 2017 for viral Hepatitis HCV - elimination on its way: dream or emerging reality? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany   ----------------------------------   CROI 2017 - Conference on Retroviruses and Opportunistic Infections (CROI) February 13-16, 2017, Seattle WA   ------------------------------------   Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012 - (04/03/17)   CROI: GLECAPREVIR AND PIBRENTASVIR INTERACTIONS WITH COMBINATION ANTIRETROVIRAL REGIMENS - (02/20/17)   CROI: High rates of hepatitis C virus cure among black and non-black persons with HIV-infection receiving care in an urban center - (03/20/17)   CROI: Correlation of Renal Biomarkers and Tenofovir AUC in the ION-4 Study Cohort - (02/20/17)   CROI:Same same but different? Risk of DAA therapy failure in real-life HCV/HIV coinfection: The GECCO Cohort - (03/20/17)   CROI: The Association Between HCV And Comorbid Conditions In 2 Large Patient Cohorts - (03/02/17)   CROI: Unrestricted Dutch Athena Cohort (HIV+/MSM/IDU) DAA Access Leads to Speedy Uptake, High Cure Rates ....'51% decrease in acute HCV, increased STD rates/syphillis'   CROI: Acute HCV Drops Sharply in HIV-Positive Dutch MSM After DAA Rollout - (03/31/17)   CROI: A Systematic HCV-RNA Screening in HIV+ MSM Reveals a High Number of Potential Transmitters: 5% HCV Prevalence, 17% acute HCV incidence, higher rates of condomless sex, IDU, syphillis - (03/07/17)   CROI: High and Rising HCV Incidence in San Diego Study of 2395 MSM With HIV - (03/07/17)   CROI: HCV REINFECTION AFTER SUCCESFUL DAA TREATMENT -A GECCO ANALYSIS - 11% HIV+ MSM - (03/20/17)   CROI: High prevalence of hepatitis C virus among HIV negative MSM in the Amsterdam PrEP project - (03/02/17)   CROI: REAL-LIFE TREATMENT RATES FOR HEPATOCELLULAR CARCINOMA IN HIV-INFECTED PATIENTS - (03/21/17)   CROI: HCC DEVELOPMENT IN HCV PATIENTS AFTER DAA: THE EXPERIENCE OF THE SCOLTA PROJECT - (03/02/17)   CROI: Liver Cancer Cases Rise After SVR With All-DAA Therapy in Spanish HCV/HIV Cohort...... "our study has not found evidence for an increased HCC incidence with DAA use" - (03/02/17)   CROI: Effectiveness of All-Oral DAAs for HCV Genotype 3 In HIV/HCV-Coinfected Patients - (03/20/17)   CROI: High Efficacy of IFN-free Anti-HCV Regimens for Individuals on Opiate Agonist Therapy - (03/22/17)   CROI: Real-world outcomes of HCV treatment in homeless and marginally housed adults - (03/20/17)   CROI: IFN-FREE THERAPY IS EFFECTIVE AND SAFE FOR HCV RECURRENCE IN LT HCV/HIV CO-INFECTION - (03/23/17)   CROI: Effectiveness of DAAs In HIV/HCV-coinfected Patients with Decompensated Cirrhosis - (03/23/17)   CROI: Efficacy and Safety of Direct Antiviral Agents in Cirrhotic HCV-HIV Coinfected Patients - (03/23/17)   CROI: Delivering HCV Cures in the FQHC Medical Home: Training a New Generation of Providers - (03/21/17)   CROI: Strategies for Utilizing Electronic Health Record to Improve Birth Cohort Testing In the Hospital Setting - (03/21/17)   CROI: Implementation of an EHR Prompt Reveals Low Adherence to HCV Birth Cohort Testing Recommendations - (03/21/17)   CROI: Similar SVR12 cure rates for patients treated for hepatitis C in FQHCs with behavioral health conditions compared to those without - (03/21/17)   CROI: HCV TREATMENT IN PEOPLE WHO INJECT DRUGS CO-LOCATED WITHIN A NEEDLE SYRINGE PROGRAM - (03/21/17)   CROI: Direct-Acting Antivirals Improve Access to Care and Cure for Patients with HIV and chronic Hepatitis C Virus from 2011-2015 - (03/20/17)   CROI: HIV-HCV Coinfection in the DAA Era: "En Route for Eradication" ? - (03/20/17)   CROI: 95% SVR Rates Using Imported Generic DAAs for Patients With Hepatitis C - (03/21/17)   CROI: Cost-effectiveness of HCV Screening and Linkage in MMT: Relevance of HIV Co-infection - (03/20/17)   CROI: Ledipasvir/Sofosbuvir Raises Tenofovir Diphosphate Concentrations in Red Cells - - (04/04/17)   HBV   CROI: INCREASED RATES OF HBV SEROCONVERSION UNDER LONG-TERM HBV ACTIVE THERAPY IN HBV/HIV - [16%] - (03/22/17)   CROI:TDF TO PREVENT PERINATAL HEPATITIS B VIRUS TRANSMISSION: A RANDOMIZED TRIAL (ITAP) - (03/22/17)